#pharmaceutical

Las empresas de biofarmacéutica están reestructurando acuerdos de licencia internacionales para reducir su exposición a las reglas de fijación de precios de Nación Más Favorecida, que vinculan los precios de medicamentos estadounidenses a los precios más bajos pagados en otros países.

Ugur Sahin and Ozlem Tureci will exit BioNTech by year-end to start a company focused on next-generation mRNA innovations.

Pharmaceutical giant GSK has agreed to buy 35Pharma, a biotech focused on pulmonary hypertension, for $950 million. The deal expands GSK's respiratory and cardiovascular portfolio with a pipeline targeting a disease that currently has limited treatment options.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.